Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Paediatric high-grade glioma (excluding diffuse midline glioma), drawn from the whole corpus: 4 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No systemic therapy has improved survival in H3 G34-mutant or H3- and IDH-wildtype tumours.
How long to continue fusion or BRAF inhibitors in children who respond, and what happens on stopping.
Radiotherapy to the developing brain costs cognition and growth; avoiding it in infants depends on drugs that reach the brain.
Small numbers make randomised trials slow; international platform trials are the answer being tried.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 9 changes by month →When this page itself was last checked or edited.
Hargrave and colleagues (JCO) report durable responses in the paediatric cohort.
Dabrafenib plus trametinib (paediatric high-grade glioma cohort 2023; tumour-agnostic approval for BRAF V600E solid tumours from age six).
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Bevacizumab added to radiotherapy and temozolomide did not improve event-free survival in newly diagnosed paediatric high-grade glioma.